Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
3.20
Oct 27 • 3:59 PM ET Dollar change+0.05 Percentage change(1.43%)
Aftermarket Close
3.21
Aftermarket • 5:39 PM ET Dollar change+0.01 Percentage change(0.31%)
Index
RUT
Market Cap
229.92M
Enterprise Value
112.78M
Income
-2.79M
Sales
53.66M
Book/sh
2.30
Cash/sh
1.64
Employees
49
IPO
Sep 09, 1997
P/E
-
Forward P/E
-
PEG
-
P/S
4.28
P/B
1.39
P/C
1.96
P/FCF
-
EV/EBITDA
-
EV/Sales
2.10
Quick Ratio
16.48
Current Ratio
21.72
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
-10.75% -14.51%
Sales past 3/5Y
-5.13% -5.42%
EPS Y/Y TTM
-103.41%
Sales Y/Y TTM
-70.13%
EPS Q/Q
-64.94%
Sales Q/Q
-49.45%
Insider Own
42.76%
Insider Trans
0.00%
Inst Own
48.75%
Inst Trans
0.54%
ROA
-1.36%
ROE
-1.49%
ROIC
-1.69%
Gross Margin
54.35%
Oper. Margin
-20.76%
Profit Margin
-5.19%
SMA20
-0.71%
SMA50
0.77%
SMA200
-24.31%
Trades
Shs Outstand
71.84M
Shs Float
41.13M
52W High
7.55 -57.64%
52W Low
2.83 13.07%
Volatility
2.75% 3.96%
ATR (14)
0.12
RSI (14)
50.35
Beta
1.09
Rel Volume
0.59
Avg Volume
693.41K
Volume
409,208
Perf Week
1.59%
Perf Month
-7.51%
Perf Quarter
-4.19%
Perf Half Y
-30.28%
Perf YTD
-40.80%
Perf Year
-57.09%
Perf 3Y
-13.88%
Perf 5Y
-31.29%
Perf 10Y
112.93%
Prev Close
3.15
Price
3.20
Change %
1.43%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Miller Larry R.General CounselMar 25 '26Option Exercise0.006,920055,438Mar 26 06:07 PM
Luckshire Daniel JExecutive VP & CFOMar 13 '26Option Exercise0.0011,5030286,567Mar 17 04:11 PM
Hruby Dennis EEVP & Chief Scientific OfficerMar 13 '26Option Exercise0.0011,4450202,492Mar 17 04:09 PM
Miller Larry R.General CounselMar 13 '26Option Exercise0.0021,261059,705Mar 17 04:07 PM
Nguyen DiemChief Executive OfficerMar 13 '26Option Exercise0.0085,0450185,796Mar 17 04:05 PM
Nguyen DiemChief Executive OfficerJan 27 '26Option Exercise0.0055,9020123,555Jan 28 04:05 PM
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
Ph.D.Dr. Diem Nguyen M.B.A.
M.B.A.Mr. Daniel J. Luckshire CPA
Executive VP & Chief Scientific OfficerDr. Dennis E. Hruby Ph.D.
J.D.Mr. Lawrence R. Miller Esq.
Senior VP & Chief Information OfficerMr. Herb Vloedman